These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31582408)

  • 21. Serum total bile acids associate with risk of incident type 2 diabetes and longitudinal changes in glucose-related metabolic traits.
    Zhu W; Wang S; Dai H; Xuan L; Deng C; Wang T; Zhao Z; Li M; Lu J; Xu Y; Chen Y; Wang W; Bi Y; Xu M; Ning G
    J Diabetes; 2020 Aug; 12(8):616-625. PubMed ID: 32220107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program.
    Mather KJ; Funahashi T; Matsuzawa Y; Edelstein S; Bray GA; Kahn SE; Crandall J; Marcovina S; Goldstein B; Goldberg R;
    Diabetes; 2008 Apr; 57(4):980-6. PubMed ID: 18192541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of fatty liver index with risk of incident type 2 diabetes by metabolic syndrome status in an Eastern Finland male cohort: a prospective study.
    Olubamwo OO; Virtanen JK; Pihlajamaki J; Tuomainen TP
    BMJ Open; 2019 Jul; 9(7):e026949. PubMed ID: 31278098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Associations of birth weight, plasma metabolome in adulthood and risk of type 2 diabetes.
    Wang W; Zhuang Z; Zhao Y; Song Z; Huang N; Li Y; Dong X; Xiao W; Huang T
    Diabetes Metab Res Rev; 2024 May; 40(4):e3803. PubMed ID: 38581399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating metabolites and the risk of type 2 diabetes: a prospective study of 11,896 young adults from four Finnish cohorts.
    Ahola-Olli AV; Mustelin L; Kalimeri M; Kettunen J; Jokelainen J; Auvinen J; Puukka K; Havulinna AS; Lehtimäki T; Kähönen M; Juonala M; Keinänen-Kiukaanniemi S; Salomaa V; Perola M; Järvelin MR; Ala-Korpela M; Raitakari O; Würtz P
    Diabetologia; 2019 Dec; 62(12):2298-2309. PubMed ID: 31584131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diabetes and branched-chain amino acids: What is the link?
    Bloomgarden Z
    J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Impact of Physical Activity on the Prevention of Type 2 Diabetes: Evidence and Lessons Learned From the Diabetes Prevention Program, a Long-Standing Clinical Trial Incorporating Subjective and Objective Activity Measures.
    Kriska AM; Rockette-Wagner B; Edelstein SL; Bray GA; Delahanty LM; Hoskin MA; Horton ES; Venditti EM; Knowler WC;
    Diabetes Care; 2021 Jan; 44(1):43-49. PubMed ID: 33444158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HDL Particle Subspecies and Their Association With Incident Type 2 Diabetes: The PREVEND Study.
    Sokooti S; Flores-Guerrero JL; Kieneker LM; Heerspink HJL; Connelly MA; Bakker SJL; Dullaart RPF
    J Clin Endocrinol Metab; 2021 May; 106(6):1761-1772. PubMed ID: 33567068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the Finnish Diabetes Prevention Study.
    de Mello VD; Paananen J; Lindström J; Lankinen MA; Shi L; Kuusisto J; Pihlajamäki J; Auriola S; Lehtonen M; Rolandsson O; Bergdahl IA; Nordin E; Ilanne-Parikka P; Keinänen-Kiukaanniemi S; Landberg R; Eriksson JG; Tuomilehto J; Hanhineva K; Uusitupa M
    Sci Rep; 2017 Apr; 7():46337. PubMed ID: 28397877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach.
    Floegel A; Stefan N; Yu Z; Mühlenbruch K; Drogan D; Joost HG; Fritsche A; Häring HU; Hrabě de Angelis M; Peters A; Roden M; Prehn C; Wang-Sattler R; Illig T; Schulze MB; Adamski J; Boeing H; Pischon T
    Diabetes; 2013 Feb; 62(2):639-48. PubMed ID: 23043162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group.
    Goldberg RB; Temprosa M; Haffner S; Orchard TJ; Ratner RE; Fowler SE; Mather K; Marcovina S; Saudek C; Matulik MJ; Price D;
    Diabetes Care; 2009 Apr; 32(4):726-32. PubMed ID: 19171717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating sex hormone binding globulin levels are modified with intensive lifestyle intervention, but their changes did not independently predict diabetes risk in the Diabetes Prevention Program.
    Aroda VR; Christophi CA; Edelstein SL; Perreault L; Kim C; Golden SH; Horton E; Mather KJ;
    BMJ Open Diabetes Res Care; 2020 Dec; 8(2):. PubMed ID: 33328161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of sex hormone-binding globulin (SHBG), testosterone, and other sex steroids, on the development of type 2 diabetes in a cohort of community-dwelling middle-aged to elderly men.
    Gyawali P; Martin SA; Heilbronn LK; Vincent AD; Taylor AW; Adams RJT; O'Loughlin PD; Wittert GA
    Acta Diabetol; 2018 Aug; 55(8):861-872. PubMed ID: 29845345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program.
    Jablonski KA; McAteer JB; de Bakker PI; Franks PW; Pollin TI; Hanson RL; Saxena R; Fowler S; Shuldiner AR; Knowler WC; Altshuler D; Florez JC;
    Diabetes; 2010 Oct; 59(10):2672-81. PubMed ID: 20682687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mahalanobis distance, a novel statistical proxy of homeostasis loss is longitudinally associated with risk of type 2 diabetes.
    Flores-Guerrero JL; Grzegorczyk MA; Connelly MA; Garcia E; Navis G; Dullaart RPF; Bakker SJL
    EBioMedicine; 2021 Sep; 71():103550. PubMed ID: 34425309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triglyceride-rich lipoprotein and LDL particle subfractions and their association with incident type 2 diabetes: the PREVEND study.
    Sokooti S; Flores-Guerrero JL; Heerspink HJL; Connelly MA; Bakker SJL; Dullaart RPF
    Cardiovasc Diabetol; 2021 Jul; 20(1):156. PubMed ID: 34321006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial.
    Diabetes Prevention Program Research Group
    Diabetes Care; 2015 Jan; 38(1):51-8. PubMed ID: 25336746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Untargeted metabolic profiling identifies altered serum metabolites of type 2 diabetes mellitus in a prospective, nested case control study.
    Drogan D; Dunn WB; Lin W; Buijsse B; Schulze MB; Langenberg C; Brown M; Floegel A; Dietrich S; Rolandsson O; Wedge DC; Goodacre R; Forouhi NG; Sharp SJ; Spranger J; Wareham NJ; Boeing H
    Clin Chem; 2015 Mar; 61(3):487-97. PubMed ID: 25524438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes.
    Goldberg RB; Temprosa MG; Mather KJ; Orchard TJ; Kitabchi AE; Watson KE;
    Diabetes Care; 2014 Aug; 37(8):2253-60. PubMed ID: 24824548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study.
    Perreault L; Pan Q; Mather KJ; Watson KE; Hamman RF; Kahn SE;
    Lancet; 2012 Jun; 379(9833):2243-51. PubMed ID: 22683134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.